Use of manzamine compounds in anti-cancer therapeutic regimens
US8232266B2 · kind B2 · utility
0Cited by
3References
1Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | Feb 20, 2007 |
| Grant date | Jul 31, 2012 |
| Priority date | — |
| Expiry date | Nov 26, 2028 |
Classification
- Technology area (CPC A)Human Necessities
- CPC primaryA61P35/04
- WIPO fieldPharmaceuticals
- WIPO sectorChemistry
Abstract
Manzamine compounds have been discovered to decrease cell dissociation and cell migration associated with the metastatic potential of cancer cells and a restoration of cancer cell susceptibility to agents, such as TRAIL, which can induce apoptosis. Specifically, Manzamine A has a formerly unrecognized utility in both blocking tumor cell invasion and tumor metastasis as well in restoring cancer cell susceptibility to standard chemotherapeutic agents which induce apoptosis and, therefore, has utility in treating cancer.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.